Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Valeant Pharma: Pershing walks away, but balance sheet strengthening should not be dismissed — Stifel (12.11)Stifel notes VRX's top holder, Pershing Square, announced the offering of its 27.2mn share stake, giving up two board seats (Bill Ackman/Stephen Fraidin) at re-election and ending what was a very public entanglement with the company since the failed bid for Allergan. VRX has since rebuilt its mgmt team, pursued asset sales to simplify the business, strengthened the balance sheet, and has refocused investment into growth assets and R&D. Despite this, the stock has continued to decline and Ackman is finally capitulating and taking the tax loss, with VRX representing ~$300mn (or <3% of its capital) down from what was a multi-billion dollar investment. This will be another sentiment hit to VRX shares, only a day after agreeing to terms on the restructuring of its Term Loan facilities and upsizing a bond financing that extends a good portion of its 2018-2020 obligations. Though the overhang of its most urgent debt maturities have been removed, VRX remains committed to its debt repayment target by early-2018, of which half remains to be satisfied through cash flow and additional divestments.<br/> <br/> VRX -12.5% premarket.</td> </tr></table>"